Natco Pharma

NATCO Pharma Ltd. is an India-based vertically integrated and R&D focused enterprise, engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs) and intermediates.

Natco Pharma
Public company
Traded asNSE: NATCOPHARM
BSE: 524816
ISININE987B01026 
IndustryPharmaceuticals
Founded1981
FoundersVC Nannapaneni
Headquarters
Hyderabad
,
India
Area served
Global
Key people
VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2]
Websitenatcopharma.co.in

Incorporated in Hyderabad in 1981 by Shri Venkaiah Chowdary Nannapaneni with an initial investment of INR 3.3 million. The Company has eight manufacturing facilities, which include 6 FDF and 2 API facilities, spread across India with dedicated modern research laboratories and capabilities in New Drug Development.

The Company focuses on niche therapeutics areas and complex products, which gives it a unique positioning in the market, spread over 40 countries. It sells FDF products in the US, India, Europe and Rest of the World (RoW); with substantial clientele in Canada and Brazil as well. It holds a leading market share in the domestic oncology segment.

NATCO is constantly driven by its mission to ‘make specialty medicines accessible to all.’ As of March 31, 2020, it employs around 5000 people.

Business Segments

NATCO operates in two businesses, FDF and APIs. Its formulations business caters to international markets as well as domestic markets, with products in oncology, pharma specialties and cardiology and diabetology (CnD).

International formulations

NATCO has more than 30 years’ expertise in the formulations business, as well as track record of success in venturing into various international markets with a healthy market share. In the US, it follows a partnership-driven business model, wherein, NATCO brings the manufacturing strength and know how and help with marketing. In Europe and the rest of the world (RoW) markets (majorly, Canada and Brazil), NATCO has been acting through its subsidiaries.

Milestones

In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[3]

In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[4]

In 2016, Natco Pharma launched Tamiflu generic capsules in the US, used for the treatment of Influenza.

In 2017, Natco Pharma launched Glatiramer Acetate in the US and also launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[5]

In 2019, Natco Pharma has initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district of Andhra Pradesh.

References
  1. "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. "Niche Play". Business Today. Retrieved 19 April 2020.
  4. "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
  5. "Natco Pharma launches blood cancer drug priced Rs 5,000-20,000, down 98% from US price - Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.